Remziye Zaim
Overview
Explore the profile of Remziye Zaim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
123
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zaim R, Redekop W, Uyl-de Groot C
Front Oncol
. 2023 Mar;
13:1027659.
PMID: 36969040
Immunotherapy offers a distinctive mechanism of action compared to traditional treatments, arising from additional value dimensions that may not be captured in standard health technology assessments. Cancer patients may have...
2.
Zaim R, Redekop W, Uyl-de Groot C
Front Health Serv
. 2023 Mar;
3:1034256.
PMID: 36926505
To assess the methodological quality of cost-effectiveness analyses (CEA) of nivolumab in combination with ipilimumab, we conducted a systematic literature review in the first-line treatment of patients with recurrent or...
3.
Zaim R, Redekop K, Uyl-de Groot C
J Cancer Policy
. 2023 Jan;
35:100382.
PMID: 36592861
Immunotherapy represents a significant breakthrough in the treatment of cancer, including non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors (ICIs) are used in combination with other treatments to provide clinically...
4.
Zaim R, Redekop K, Uyl-de Groot C
J Cancer Policy
. 2022 Jul;
33:100346.
PMID: 35779788
Regulatory authorization of oncology drugs, including immune-checkpoint inhibitors, is often based on enhanced efficacy and acceptable toxicity profiles, investigated in randomized, open-label clinical trials. Regulatory approval decisions of the United...
5.
Zaim R, Redekop K, Uyl-de Groot C
Transl Oncol
. 2022 Apr;
20:101418.
PMID: 35429903
In the era of value-based oncology care, stakeholders are increasingly using patient reported outcomes (PROs) to guide clinical and regulatory decisions. PROs are also included in health technology assessments to...
6.
Holleman M, Al M, Zaim R, Groen H, Uyl-de Groot C
Eur J Health Econ
. 2019 Sep;
21(1):153-164.
PMID: 31541309
Objectives: To compare the cost-effectiveness of first-line gefitinib, erlotinib, afatinib, and osimertinib in patients with non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutations. Methods: A systematic...
7.
Westwood M, Lang S, Armstrong N, van Turenhout S, Cubiella J, Stirk L, et al.
BMC Med
. 2017 Oct;
15(1):189.
PMID: 29061126
Background: This study has attempted to assess the effectiveness of quantitative faecal immunochemical tests (FIT) for triage of people presenting with lower abdominal symptoms, where a referral to secondary care...
8.
Westwood M, Corro Ramos I, Lang S, Luyendijk M, Zaim R, Stirk L, et al.
Health Technol Assess
. 2017 Jun;
21(33):1-234.
PMID: 28643629
Background: Colorectal cancer (CRC) is the third most common cancer in the UK. Presenting symptoms that can be associated with CRC usually have another explanation. Faecal immunochemical tests (FITs) detect...
9.
Maan R, Zaim R, van der Meer A, Feld J, Wedemeyer H, Dufour J, et al.
J Gastroenterol Hepatol
. 2016 Mar;
31(11):1851-1859.
PMID: 26990109
Background And Aims: Very potent direct acting antivirals for the treatment of chronic hepatitis C virus infection were recently introduced into daily clinical practice. Currently, treatment uptake is hampered by...